Related Experiment Video
Updated: Apr 27, 2026
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
Published on: March 6, 2012
A GSK-3β inhibitor protects against radiation necrosis in mouse brain
Xiaoyu Jiang1, Carlos J Perez-Torres2, Dinesh Thotala3
1Department of Chemistry, Washington University, St. Louis, Missouri.
Purpose:
To quantify the effectiveness of SB415286, a specific inhibitor of GSK-3β, as a neuroprotectant against radiation-induced central nervous system (brain) necrosis in a mouse model.
Methods And Materials:
Cohorts of mice were treated with SB415286 or dimethyl sulfoxide (DMSO) prior to irradiation with a single 45-Gy fraction targeted to the left hemisphere (brain) using a gamma knife machine. The onset and progression of radiation necrosis (RN) were monitored longitudinally by noninvasive in vivo small-animal magnetic resonance imaging (MRI) beginning 13 weeks postirradiation. MRI-derived necrotic volumes for SB415286- and DMSO-treated mice were compared. MRI results were supported by correlative histology.
Results:
Mice treated with SB415286 showed significant protection from radiation-induced necrosis, as determined by in vivo MRI with histologic validation. MRI-derived necrotic volumes were significantly smaller at all postirradiation time points in SB415286-treated animals. Although the irradiated hemispheres of the DMSO-treated mice demonstrated many of the classic histologic features of RN, including fibrinoid vascular necrosis, vascular telangiectasia, hemorrhage, and tissue loss, the irradiated hemispheres of the SB415286-treated mice consistently showed only minimal tissue damage. These studies confirmed that treatment with a GSK-3β inhibitor dramatically reduced delayed time-to-onset necrosis in irradiated brain.
Conclusions:
The unilateral cerebral hemispheric stereotactic radiation surgery mouse model in concert with longitudinal MRI monitoring provided a powerful platform for studying the onset and progression of RN and for developing and testing new neuroprotectants. Effectiveness of SB415286 as a neuroprotectant against necrosis motivates potential clinical trials of it or other GSK-3β inhibitors.
Insights
SB415286, a GSK-3β inhibitor, effectively protected mouse brains from radiation-induced necrosis. This neuroprotectant significantly reduced necrotic volumes and tissue damage, suggesting potential for clinical trials in brain radiation therapy.
Area of Science:
- Neuroscience
- Radiation Oncology
- Pharmacology
Background:
- Radiation therapy for brain tumors can cause central nervous system (CNS) necrosis.
- Developing effective neuroprotectants is crucial to mitigate radiation-induced brain damage.
- Glycogen synthase kinase 3 beta (GSK-3β) is implicated in cellular damage pathways.
Purpose of the Study:
- To evaluate SB415286, a GSK-3β inhibitor, as a neuroprotectant against radiation-induced brain necrosis.
- To quantify the protective effects of SB415286 in a preclinical mouse model.
Main Methods:
- Mice received SB415286 or DMSO before targeted brain irradiation.
- Radiation necrosis (RN) onset and progression were monitored using longitudinal in vivo magnetic resonance imaging (MRI).
- MRI findings were validated with correlative histology.
Main Results:
- SB415286 treatment significantly reduced radiation-induced necrotic brain volumes compared to controls.
- Histological analysis confirmed minimal tissue damage in SB415286-treated mice.
- GSK-3β inhibition dramatically delayed the onset of necrosis in irradiated brain tissue.
Conclusions:
- SB415286 demonstrates significant neuroprotective efficacy against radiation-induced necrosis.
- The mouse model with longitudinal MRI is effective for studying and developing neuroprotectants.
- These findings support further investigation of SB415286 and other GSK-3β inhibitors for clinical trials.
